Purchase Order 75N95024P00504

Award Date 9/4/24
Potential Completion Date 9/17/24
Potential Value $17K
Contracting Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98121, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $172,800.00 firm fixed price purchase order to Curi Bio Inc., a for-profit small disadvantaged business, for the acquisition of a Mantarray Magnetometric Analyzer for Engineered Tissue Arrays. This specialized equipment will be used to support biomedical research programs within the NIH, including efforts to develop human cell-based platforms for drug discovery...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $509,165.70 firm-fixed-price purchase order to Government Scientific Source Inc. for the delivery of a Mass Cytometry Imaging System. This system will be used by the National Center for Advancing Translational Sciences (NCATS) Stem Cell Translation Laboratory to support their research on induced pluripotent stem cells. The contract is not set aside for any special business...
This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the Department of Health and Human Services (HHS), to Mimetas Operations US, Co., a foreign-owned, self-certified small disadvantaged business. The $150,480.00 contract is for the acquisition of Organoplate Grafts, which are microfluidic 3D cell culture plates used in scientific research projects related to SARS-CoV-2 and COVID-19. This contract was...
This is a $299,986.00 firm-fixed-price contract awarded by the National Cancer Institute, a component of the U.S. Department of Health and Human Services, to Nortis Inc., a small business manufacturer of biotechnology products and services. The contract is for administrative support services, which is designated as a total small business set-aside. Nortis Inc. has previously received federal grants and contracts from agencies such as the National Institute of Environmental Health Sciences and...
This is a $23,906 firm fixed price purchase order awarded to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of biologically relevant human cells derived from induced pluripotent stem cells (iPSCs). The award is from the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH) within the Department of Health and Human Services. The contract is for the delivery of various iPSC-derived cell types, such as...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a Firm Fixed Price purchase order contract worth $265,048.50 to Life Technologies Corporation, a for-profit manufacturer of scientific instruments, reagents, and consumables. The contract is for the delivery of assorted cell culture medium, substrate, and supplements manufactured by Life Technologies. This contract supports the Stem Cell Translation Laboratory within the National...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a $150,000.00 firm fixed-price purchase order to 3Dnamics Inc., a biotechnology company, for services related to the differentiation and characterization of induced pluripotent stem cell (iPSC) lines. This non-competitive commercial item acquisition was conducted under simplified acquisition procedures without a small business set-aside. The services...
This is a $99,715.40 firm fixed-price purchase order awarded to Cisbio US, Inc., a foreign-owned for-profit company, by the National Institute on Drug Abuse (NIDA), a civilian agency within the Department of Health and Human Services (HHS). The contract is for the provision of assay kits, cell lines, and collagen reagents to support research activities. This award was not set aside and is the latest in a series of similar purchase orders awarded to Cisbio US, Inc. to provide biomarker...
This is a $124,070 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the U.S. Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell (iPSC) derived human cell products. The contract is for the delivery of iPSC-derived human neurons and astrocytes, which are biologically relevant cell types used to support biomedical...
This is a firm-fixed-price purchase order award to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer, by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services. The $79,825 contract is for the supply of 50 iCell Motor Neurons Kits, brand-name products from Fujifilm Cellular Dynamics, to support research initiatives including drug development, toxicology screening, and the creation of...

This $17,020 firm fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, to Curi Bio Inc., a small disadvantaged business manufacturer. The contract is for the delivery of 3D IPSC skeletal muscle media kits, which will support biomedical research and drug development programs at NCATS. Curi Bio has previously received other federal contracts and grants from the National Institutes of Health to provide cell-based platforms, instrumentation, and services to enable preclinical drug safety screening and disease modeling. This award does not utilize any set-aside designations, and the period of performance runs through September 17, 2024.

Generated 8/29/24, 9:18 AM